Browsing by Author "Yurtdas, M."
Now showing 1 - 3 of 3
- Results Per Page
- Sort Options
Conference Object The Clinical Features, Risk Factors and Treatment Methods of Patients With Acute Coronary Syndrome(Excerpta Medica inc-elsevier Science inc, 2014) Aladag, N.; Yurtdas, M.; Ozdemir, M.; Gonullu, H.; Babat, N.; Demir, G.; Gumrukcuoglu, H.Article Dabigatran Versus Warfarin in Atrial Fibrillation: Multicenter Experience in Turkey(Sage Publications inc, 2016) Aslan, Onur; Yaylali, Y. T.; Yildirim, S.; Yurtdas, M.; Senol, H.; Ugur-Yildiz, M.; Ozdemir, M.Safety issues have been raised about dabigatran. We aimed to investigate the occurrence of safety outcomes in patients who had atrial fibrillation and a risk of stroke. We analyzed 439 patients prescribed dabigatran (n = 220) or warfarin (n = 219). Ischemic stroke occurred in 15 (6.8%) patients in the warfarin group versus 5 (5.2%) patients in the 110-mg group versus 1 (0.8%) patient in the 150-mg dabigatran group (P = .015). Intracranial hemorrhage occurred in 6 (2.7%) patients in the warfarin group versus 3 (2.4%) patients in the 150-mg dabigatran group (P = .104). Death from any cause occurred in 10 (4.6%) patients in the warfarin group versus 1 (1.0%) patient in the 110-mg dabigatran group (P = .005). Dabigatran was associated with less ischemic stroke and death from any cause than warfarin. Dabigatran may be a better option for stroke prophylaxis, where recommended monitoring with warfarin is suboptimal.Conference Object Transradial Primary Percutaneous Coronary Intervention Is Associated With Low Rates of Clinical and Cardiovascular Events in Patients With Acute St Elevation Myocardial Infarction(Excerpta Medica inc-elsevier Science inc, 2014) Yurtdas, M.; Kaya, Y.; Ozdemir, M.; Aladag, N.; Tosu, A. R.; Tuncer, M.
